TNF and COVID-19: First reports suggest that administration of MSCs is safe in patients with ARDS (Zheng et al., 2014) and may limit the cytokine storm (by reducing the levels of C-Reactive Protein, IL-6 or TNF-α) and improve oxygenation in severe COVID-19 patients (Sengupta et al., 2020).